Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

High-grade ovarian cancer: ctDNA positivity after frontline therapy independently tracked with shorter PFS

An ASCO 2026 retrospective cohort of 72 patients with high-grade epithelial ovarian cancer, 69 of whom were in clinical remission, found ctDNA positivity in 30 and second-look laparoscopy positivity in 33; on multivariable analysis ctDNA positivity predicted shorter progression-free survival (HR 4.35; 95% CI 2.17 to 8.72).

Journal of Clinical Oncology